[The behavior of blood clotting and its inhibitors under long term treatment with 5,6-benzo-alpha-pyrone (coumarin). Double blind study].
The analyses on hemostaseological variables are recorded in connection with blood tests in the course of a double-blind study in 41 patients suffering from chronic venous insufficiency of higher degrees of severity. They were treated in addition to compression measures with two active ingredients, a coumarin (5,6-benzo-alpha-pyrone)/troxerutin combination (Venalot Depot) (n = 20) or benzarone (n = 21) receiving 3 X 2 dragees daily for 6 weeks. Good clinical efficacy and the improvement of symptoms were observed together with almost no side-effects. The coagulation analysis showed no influence of the active principles on the global coagulation or the clotting factors and the inhibitors and factors of the fibrinolysis. In particular there was no phenprocoumon-like effect on the blood clotting system.
D000925:Anticoagulants / Q000627:therapeutic use*; D001553:Benzbromarone / Q000031:analogs & derivatives / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003374:Coumarins / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010314:Partial Thromboplastin Time; D011897:Random Allocation; D012431:Rutin / Q000031:analogs & derivatives*; D013997:Time Factors; D014689:Venous Insufficiency / Q000188:drug therapy*
D000925:Anticoagulants; D003374:Coumarins; D004338:Drug Combinations; D006896:Hydroxyethylrutoside; C004528:benzarone; C013731:Venalot; D001553:Benzbromarone; D012431:Rutin
Das Verhalten der Blutgerinnung und deren Inhibitoren unter Langzeitbehandlung mit 5,6-Benzo-alpha-pyron (Cumarin). Doppelblindstudie.